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generated based on the not-edited auto-contours. These plans were 
than evaluated on the edited auto-contours by two different 
observers.   
Results: Atlases used for auto-segmentation should carefully be 
selected, and validated in great detail to reach the most accurate 
segmentations. Compared to the use of a single-subject atlas, 
application of a multi-subject atlas improved the accuracy of the 
auto-contours. In the clinical validation study, an expert panel scored 
all auto-contours as ‘minor deviation, editable’ or better.  Compared 
to manual contouring, editing auto-contours reduced the hands-on 
time from 180 to 66 minutes. The dosimetric study showed that 
editing of auto-contoured neck CTV was inevitable to avoid (large) 
underdosages in the target, even when differences between the auto-
contoured and edited structures were small. For salivary glands, the 
necessity of editing the auto-contours was less pronounced.  
Currently we are using ABAS for auto-segmentation for most 
treatment sites (head-and-neck, neurology, lung, prostate, breast). 
ABAS is also used for adaptive treatments, when a patient needs a 
new CT due to anatomical changes. By using the initially segmented 
CT set as atlas, a high-quality structure set can automatically be 
generated for the new CT in very short time, hardly needing any 
manual editing of the contours. To realize a high throughput of ABAS, 
and to minimize human errors in its use, we developed an interface to 
run ABAS in a semi-automated way. 
Conclusions: Multi-atlas based auto-contouring of CTV images proved 
to be a very useful tool for rapid delineation of target volumes and 
normal tissues. Although editing of auto-contours is inevitable, 
especially for the target, a substantial time reduction is achieved 
when editing auto-contours, instead of manually contouring from 
scratch.  
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If the radiation-induced fibrotic (RIF) process involves irradiated 
tissues and organs, it is only highly symptomatic in some sparse 
delayed and irreversible local sequelae. Severity often depends on 
treatment-related factors, as radiotherapy dose-volume, combined 
chemotherapy, or combined major surgery (hematoma-lymphedema-
infection), and/or patient’s co-morbidities. There is a 
histopathological heterogeneous patchwork comprising concomitant 
active cellular areas and sclerotic matricial areas, describing a 
defective healing with overwhelmed defenses mechanisms [1]. 
Therapeutic clinical experience is dependent on the severity of 
radiation-induced fibrosis at baseline, the quality of clinical 
assessment (best scoring), the availability of effective drugs, and 
sufficient treatment duration (minimum 6 months) for a chronic 
disease (quality of trial design). Management of radiation-induced 
sequelae should include: reduction of co-morbidity factors, plus 
control of any acute inflammation (infection, traumatism..) that 
worsens the underlying injury, plus use of antifibrotic agents [2], and 
promotion of tissue regeneration.  
For moderate cases, medical management is based on an initial anti-
inflammatory treatment with steroids ± antibiotics (repeated for any 
acute phase) that promotes further drug penetration in the irradiated 
volume, followed by a pentoxifylline-tocopherol combination [3,4] (or 
statins) to reduce fibroproliferative “heart” sequelae, boosted by an 
organ-targeted drugs (antiseptic for enteritis, physiotherapy and 
gabapentin for neuromuscular disease,…) to control specific symptoms 
(microbial proliferation, neuromuscular irritation...).  
For severe injury including fibrosis and necrosis, management is again 
based on a first anti-inflammatory treatment; followed by vascular 
therapy (pentoxifylline, HBO, heparin, ACE inhibitors); or antifibrotic 
treatments especially PENTOCLO (combined pentoxifylline-tocopherol-
clodronate) best described in osteoradionecrosis [5]; or anticytokines 
(TGFb or TNF); and regenerative option (dead tissue removal, stem 
cell mobilization, graft). 
Controlled trials are necessary to identify useful drugs and their 
optimal combination (best strategy). However, to help patients with 
severe injuriy (pain, handicap, compression), we should always reduce 
radiation-induced fibrosis and also seek to compensate for tissue 
depletion by graft or cell regeneration, while taking into account 
organ specificities. 
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Idiopathic pulmonary fibrosis (IPF) is the most frequent idiopathic 
interstitial lung disease. IPF is a rare and severe disease. Estimated 
annual incidence is 5/100 000 and median survival is 3 years. Diagnosis 
depends on clinical data (absence of a cause) a possible or typical 
Usual Interstitial Pneumonia (UIP) pattern on chest High Resolution 
CTscan, and a UIP pattern on lung biopsy, if performed (Raghu, Am J 
Respir Crit Care Med 2011; 183:788-824). In Europe a combination of 
prednisone, azathioprine and N-acetyl cysteine was the standard of 
care in IPF patients requiring a treatment, on the basis of the IFIGENIA 
study (Demedts, New Engl JMed 2005;353:2229-42). The IFIGENIA 
study compared the triple therapy with the combination of 
prednisone, azathioprine and placebo, and showed that the triple 
therapy reduced lung function decline. However, this triple therapy 
was recently shown to be harmful as compared to placebo (IPF clinical 
research network, NewEngl J Med 2012;366:1968-77).   
Currently pirfenidone is the only drug approved for the treatment of 
IPF. This drug is available in Japan since 2008, and in some European 
countries since 2011. The approval of pirfenidone by the European 
Medicines Agency was based upon three phase III trials, one in Japan 
(Taniguchi, Eur Respir J 2010;35:821-9), and two in European-North 
American countries (the CAPACITY trials) (Noble, Lancet 2011; 
377:1760-9).  Both studies showed that pirfenidone reduced the 
decline of lung function as evaluated by forced vital capacity. In the 
CAPACITY trials, there was also a reduction in the decline of the 6 
minutes walking distance, and a trend for an improved survival in the 
treated group. Tolerance of pirfenidone is acceptable with 
gastrointestinal (nausea, dyspepsia) and skin (photosensitivity, rash) 
side effects. The mode of action of pirfenidone is unknown. However 
pirfenidone has consistently demonstrated anti fibroticaction in 
different experimental models of lung (e.g. bleomycin-induced lung 
injury), heart, vessels and kidney fibrosis.  
Many other molecules are being evaluated in therapeutic trials in IPF. 
Nintedanib (also known as BIBF 1120) is currently being evaluated in 
two phase III trials, after a successful phase II study (Richeldi, New 
Engl J Med 2011; 365:1079-87). In that study, treatment with 
nintedanib (150mg twice daily) reduced lung function decline and 
decreased the incidence of acute exacerbation of IPF. Gastrointestinal 
side-effects requiring the cessation of the drug were observed in 
about 16% of the patients.  Nintedanib is a tyrosine kinase inhibitor 
targeting VEGFR, PDGFR, FGFR, and other kinases.  
Many more molecules are being evaluated in phase I and phase II 
studies (see www.clinicaltrials.gov). Most of these molecules are 
targeting one specific pathway among many pathways which have 
been shown to be activated in IPF and in experimental models 
ofpulmonary fibrosis. In the past, many molecules have failed (e.g. 
endothelin receptor antagonists, PDGFR antagonist, anti-TNF, 
warfarin, …). We hope that the new molecules being tested will 
finally allow for the improvement of IPF survival in the next future.  
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The transforming growth factor beta (TGF-β) signalling pathway plays 
a central role in the development of normal tissue fibrosis after 
irradiation. TGF-β is a key regulator of cell growth and 
differentiation; it affects the immune system and controls the 
homeostasis of extracellular matrix. Accordingly, mice lacking the 
TGF-β signalling intermediate Smad3 are protected from irradiation-
induced skin, liver and lung fibrosis. Moreover, knockdown of the TGF-
β/Smad3 downstream target Pai-1 protects mice from fibrosis after 
intestinal irradiation. Although radiation fibrosis has been extensively 
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studied, the mechanisms of its initiation and chronic extension still 
remain to be resolved. Yet, it is clear that development of fibrosis 
after radiation cannot simply be explained by the function of one 
molecule, but requires the interplay of several cytokines and growth 
factors and multiple cell types.  
Our studies have identified the TGF-β co-receptor endoglin as new 
player in radiation-induced fibrosis development in the kidney. Mice 
expressing halved levels of endoglin (Eng+/-mice) displayed reduced 
fibrosis, but also less vascular damage after a single dose of kidney 
irradiation compared to irradiated Eng+/+ mice. This was accompanied 
by decreased mRNA expression of Tgfb1 and pro-fibrotic downstream 
targets such as Pai-1, Ctgf or Col3A1. We also noticed that 
development of fibrosis in the kidney was accompanied by infiltration 
of inflammatory cells, mainly macrophages. Macrophages are crucial 
for tissue repair, but may also promote kidney fibrosis by secreting 
pro-fibrotic growth factors and cytokines as shown in several models 
of kidney disease. Macrophage numbers were significantly upregulated 
in both irradiated Eng+/+ and Eng+/- kidneys; however, the upregulation 
was less pronounced in Eng+/- mice. In addition, expression of 
macrophage-expressed pro-inflammatory, pro-fibrotic and anti-
angiogenic cytokines interleukin 1-beta (Il1b) and interleukin 6 (Il6) 
was strongly reduced in the irradiated kidneys of Eng+/- compared to 
Eng+/+ mice.  
As endoglin is not only expressed on endothelial cells, but also on 
monocytes/macrophages, we are currently investigating whether 
changed endothelial cell function or an altered macrophage 
phenotype contributes to differential fibrosis formation in Eng+/+ and 
Eng+/-mice. We are also analysing whether macrophage depletion 
prevents fibrosis formation after kidney irradiation. Furthermore, we 
are testing whether the anti-inflammatory, immunomodulatory and 
anti-fibrotic drug Thalidomide impedes the development of radiation-
induced kidney fibrosis. 
In summary, we suggest that endoglin mediates the inflammatory 
response in irradiated tissues by regulating macrophage infiltration 
and cytokine production thereby contributing to the development of 
irradiation-induced kidney fibrosis.  
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Brachytherapy has benefited considerably from advances in imaging 
techniques in recent times. Tumour volumetric-based radiation 
planning based on excellent delineation of tumour anatomy has much 
improved our ability to target malignant tissue whilst sparing non-
malignant tissues. The highly conformal nature of Brachytherapy has 
further benefited from newer functional imaging techniques based on 
recognition of the altered biological and molecular processes 
occurring within tumour tissue. New paradigms for treatment planning 
and radiation delivery are now becoming possible based on the 
potential to define areas of varying functional activity within the 
anatomical tumour mass. Established 3D tumour volumes generated by 
morphological imaging techniques can now be modified by new 
information provided by functional imaging such as PET and MRI. 
Brachytherapy for prostate and Head & Neck cancers can benefit from 
data that quantifies areas of cellular and molecular disruptions within 
the tumour mass and thus offers the potential to individualise the 
Brachytherapy radiotherapy plan for each patient. 
Prostate Brachytherapy includes both High Dose Rate and Low Dose 
Rate techniques and has become widely adopted as a valid treatment 
for prostate tumours. Historically, imaging has played a relatively 
small role in the management of clinically localized prostate cancer 
but in more recent years, medical imaging techniques, such as TRUS, 
CT and MRI have improved the clinical management of patients with 
prostate cancer. Brachytherapy offers the possibility of better local 
treatment with less morbidity and improved outcomes; more accurate 
imaging has contributed to better staging and patient selection as well 
as more accurately image-guided treatment delivery.  
In the non-surgical treatment of head and neck tumours, 
Brachytherapy offers an excellent treatment for organ-preservation 
with local tumour control. Image guidance is central to the 
optimization of this treatment with careful dose escalation facilitated 
by accurate delineation of tumour and structures at risk. Adaptive 
image-guided Head & Neck Brachytherapy can complement newer 
surgical techniques and better understanding of tumour biology in this 
area will incorporate newer boost techniques also. 
The inherent goal of Brachytherapy is to safely deliver adequate 
radiation to those  areas of tumour tissue that are considered 
necessary based on our current understanding of tumour biology and 
radiation response. Imaging is central to the success of this 
treatment. 
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Before the era of breast conservation therapy using external beam 
radiotherapy (EBRT) and before the invention of linear accelerators 
and its widespread use in breast cancer treatment, brachytherapy 
using radium needles was the first method of breast irradiation. 
Interstitial breast implants started at the beginning of the XXth 
century either as mono-therapy or associated to surgery.  
Over the years, breast brachytherapy was less and less used but  it 
remained an option as a boost toEBRT. Nowadays with the increase 
use of partial breast irradiation, breast brachytherapy is gaining more 
importance.  Unlike prostate, breast brachytherapy is not widely 
practiced because it was always considered by many to be too 
operator and skill- dependent, partly because of the lack of easy and 
precise imaging.  It is evident that for more accuracy, imaging is 
necessary in breast brachytherapy as it is in EBRT, to plan and 
optimize the treatment. The need of accuracy is even more important 
in brachytherapy because it provides the most conformal coverage of 
tumor and normal tissue sparing radiotherapy technique.  
So in this era of highly targeted radiotherapy, breast brachytherapy 
faces the same challenges of volume delineation at each step of the 
process: in pre-planning, during implant and at dosimetry. The first 
step is the identification of the surgical bed to be implanted. This is 
not an easy task as reflected by the numerous papers in the 
literature. At the time of brachytherapy the cavity is often collapsed 
and difficult to find. We conducted a phase II study Using MRI imaging 
to help in the delineation of the surgical bed and therefore help to 
plan precisely where to place the implant. The second step is the 
precise placement of the interstitial needles into the breast around 
the target. This is of great importance since it will, in a way, 
determined the dosimetry. Ultrasound can be used as a step-by-step 
procedure. As in prostate brachytherapy a real-time imaging during 
the procedure would be ideal. The ultimate step, the dosimetry, is to 
maximize the dose to the target volumes and to minimize the dose to 
the adjacent organs at risk. At this step the quality of imaging is 
important for the delineation of the volumes and for reconstruction of 
the material implanted. CT scan allows implant reconstruction very 
easily but MRI allows accurate surgical bed delineation. Therefore a 
robust image fusion capacity has to be available.  Ultimately, the goal 
would be to find a 3D imaging modality that could serve both purposes 
and couldbe integrated in the treatment planning system. 
This presentation is aimed to determine the role of modern imaging 
modalities in all the steps of interstitial breast brachytherapy. It is our 
opinion that more accurate imaging will help the wide application of 
interstitial brachytherapy for breast cavity boost, partial breast 
irradiation and second conservative treatment for in-breast 
recurrences.  
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The ARTFORCE project (Adaptive and innovative Radiation Treatment 
FOR improving Cancer patients treatment outcomE) that now runs for 
more than a year, consists of two clinical trials, combined with 
fundamental research in molecular biology, i.e. predicting tumour 
response and physics: image guidance and dosimetry performed in a 
multi-institutional environment.   
The non-small cell lung cancer study aims to improve local control and 
test the hypothesis of iso-toxic dose redistribution. Patients are 
